- $99.05m
- $90.48m
- $0.18m
Annual balance sheet for Entera Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 8.59 | 24.9 | 12.3 | 11 | 8.66 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.255 | 0.183 | 0.246 | 0 | 0.126 |
| Total Other Current Assets | |||||
| Total Current Assets | 9.11 | 25.3 | 12.8 | 11.3 | 8.97 |
| Net Property, Plant And Equipment | 0.566 | 0.395 | 0.229 | 0.488 | 0.332 |
| Other Long Term Assets | |||||
| Total Assets | 9.72 | 26 | 13.1 | 11.8 | 9.39 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.84 | 3.16 | 1.34 | 1.09 | 1.18 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.21 | 3.42 | 1.37 | 1.38 | 1.31 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 7.51 | 22.6 | 11.8 | 10.4 | 8.08 |
| Total Liabilities & Shareholders' Equity | 9.72 | 26 | 13.1 | 11.8 | 9.39 |
| Total Common Shares Outstanding |